// App-Quantinova.ai

TPS450 : MEKiAUTO: A phase I/II open-label study of combination therapy with the MEK inhibitor cobimetinib, Immune-checkpoint blockade with atezolizumab, and the AUTOphagy inhibitor hydroxychloroquine in KRAS-mutated advanced malignancies.

Researchers

Presenter

  • Alexander Raufi

Principal Investigators

  • Winston Wong

  • Shing Mirn Lee

  • Gulam Abbas Manji

Medical Centers

  • Brown University, Lifespan Cancer Institute, Providence, RI

  • Columbia University Medical Center, New York, NY

  • Columbia Univ Coll of Physicians and Surgeons, New York, NY

  • Columbia University Medical Center and Herbert Irving Comprehensive Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • Hydroxychloroquine

  • Atezolizumab

  • Cobimetinib

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

Phase

  • I/II

Study Id's

  • NCT04214418

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved